Browse by year:
Reddys Acquires Trigenesis
si Team
Thursday, June 26, 2008
Indian pharma major Dr. Reddy’s Laboratories acquired Trigenesis Therapeutics,Inc., a US-based privately owned dermatology company. This will allow Dr. Reddy’s to get a firm toehold on the prescription dermatology market.
The company will now get access to products and propreitary drug delivery technology platforms for developing a pipeline of differentiated drugs in the dermatology segment. The total investment outlay is $11 million. Dr. Reddy’s will also have to continue making payments to Skye Pharma Plc, and SilvaFoam LLC, according to existing areements those companies have with Trigenesis.

Trigenesis is primarily a drug development company with rights and licenses on various propretary drug delivery technologies. Dr Reddy’s Labs withdrew its challenge on the patent for Glaxo SmithKline’s anti-nausea drug Zofran. This means Dr. Reddy’s will not be able to enter the market for the drug till the patent expires, which is to happen in 2005.
Share on LinkedIn